Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EMD Serono Research & Development Institute, Inc.
With
Merck KGaA, Darmstadt, Germany
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Greater than or equal to (\>=)18 years of age
Biopsy-proven Immunoglobulin (IgA) nephropathy
Urine Protein to Creatinine Ratio (UPCR) \>= 0.75 and \<= 6 milligram per milligram (mg/mg) during screening
Stable and optimal dose of Angiotensin converting enzyme (ACE) inhibitor and/or angiotensin II receptor blockers (ARB) at least 8 weeks prior to screening
You may not be if
Concomitant significant renal disease other than IgA nephropathy
IgA nephropathy with significant glomerulosclerosis or cortical scarring
Diagnosis of Henoch-Schonlein purpura
Failure to meet estimated glomerular filtration rate (eGFR) and biopsy requirement criteria
Serum IgG below 6 grams per liter (g/L)
Use of cyclophosphamide ever or use of other immunosuppressants or systemic corticosteroids within 4 months
Active infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks
History, or current diagnosis, of active tuberculosis (TB), or untreated latent TB infection
History of or positive HIV and/or positive for hepatitis B or Hepatitis C at screening
History of malignancy
Nursing or pregnancy
Any condition, including any uncontrolled disease state other than IgA nephropathy
Clareo Health | Efficacy and Safety of Atacicept in IgA Nephropathy
